TABLE 5.
In vitro permeability and metabolism results for BI 201335, telaprevir, and boceprevir
| Inhibitor | Caco-2 cell permeabilitya (106 cm/s) |
LM metabolic CL (% Qh) in the following animalb: |
||||
|---|---|---|---|---|---|---|
| A-to-B permeability | B-to-A permeability | Human | Rat | Monkey | Dog | |
| BI 201335 | 8.7 | 8.1 | 16.5 | <5.6 | 18.6 | <10.9 |
| Telaprevir | 4.1 | 23 | 64 | 41 | ND | ND |
| Boceprevir | 0.6 | 23 | 56 | ND | ND | ND |
a
A-to-B permeability, apical-to-basolateral permeability; B-to-A permeability, basolateral-to-apical permeability.
b
LM metabolic CL, liver microsome (LM) metabolic clearance (CL) as a percentage of hepatic blood flow (% Qh). ND, not determined.